title: Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain.
abstract: BACKGROUND
  The mechanism that predisposes patients with atopic dermatitis (AD) to disseminated vaccinia viral (VV) skin infection after smallpox vaccination is unknown. We have demonstrated that expression of S100A11, a calcium-binding protein involved in keratinocyte differentiation, is downregulated in AD.
  
  
  OBJECTIVE
  We investigated whether inhibiting expression of S100A11 increased VV replication in human keratinocytes and the mechanism by which S100A11 affects the innate immune response of keratinocytes.
  
  
  METHODS
  Small interfering RNA duplexes were used to reduce gene expression of S100A11 in keratinocytes. VV replication was evaluated by real-time PCR and viral plaque assay. VV cytopathic effect was assessed by crystal violet staining. Affymetrix GeneChip assay was used to compare gene expression profiles. Real time PCR, Western blotting, and immunohistochemistry staining assay were used to evaluate gene expression in keratinocytes and AD skin biopsies.
  
  
  RESULTS
  Keratinocytes with deficient S100A11 expression supported increased VV replication and manifested augmented VV cytopathic effects. Gene microarray analysis revealed that the IL-10 receptor 2 chain (IL-10R2), which binds IFN-lambdas, was downregulated by 2.26-fold in S100A11-silenced keratinocytes. IL-10R2 expression was found to be decreased in skin biopsies from patients with acute AD (mean, 25.21 +/- 5.25; n = 20) compared with skin from normal healthy subjects (mean, 137.1 +/- 34.46; n = 19; P < .01). Furthermore, deficient S100A11 gene expression significantly impaired IL-29 (IFN-lambda1) responsiveness (2' 5'-oligoadenylate synthetase and Myxovirus [influenza virus] resistance induction) and its anti-VV effects in keratinocytes.
  
  
  CONCLUSIONS
  Inhibition of S100A11 gene expression impairs the ability of keratinocytes to control VV replication via downregulation of IFN-lambda receptor IL-10R2.
authors: Department of Pediatrics, National Jewish Health, Denver, Colo 80206, USA.
authors: Lianghua
authors: L
authors: Bin
authors: Michael D
authors: MD
authors: Howell
authors: Byung Eui
authors: BE
authors: Kim
authors: Clifton F
authors: CF
authors: Hall
authors: Joanne E
authors: JE
authors: Streib
authors: Donald Y M
authors: DY
authors: Leung
mesh_terms: D000328:Adult; D002460:Cell Line; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D003876:Dermatitis, Atopic / Q000276:immunology* / Q000821:virology; D015536:Down-Regulation; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D006801:Humans; D007113:Immunity, Innate; D015603:Keratinocytes / Q000276:immunology / Q000821:virology*; D034741:RNA, Small Interfering / Q000378:metabolism; D053701:Receptors, Interleukin-10 / Q000378:metabolism*; D009418:S100 Proteins / Q000235:genetics* / Q000378:metabolism; D014615:Vaccinia / Q000276:immunology* / Q000821:virology; D014616:Vaccinia virus / Q000502:physiology; D014779:Virus Replication
chemical_list: D016207:Cytokines; D034741:RNA, Small Interfering; D053701:Receptors, Interleukin-10; D009418:S100 Proteins; C072337:S100A11 protein, human